New insights into cancer immunoediting and its three component phases-elimination, equilibrium and escape

Current Opinion in Immunology

Volumn 27, Issue 1, 2014, Pages 16-25

  Mittal, Deepak ^a   Gubin, Matthew M ^b   Schreiber, Robert D ^b   Smyth, Mark J ^a,c  

^a QIMR BERGHOFER MEDICAL RESEARCH INSTITUTE   (Australia)

^b WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF QUEENSLAND   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ANIMALS; DISEASE PROGRESSION; HUMANS; IMMUNOTHERAPY; NEOPLASMS; PROGNOSIS; TUMOR ESCAPE; TUMOR MARKERS, BIOLOGICAL;

EID: 84894107349     PISSN: 09527915     EISSN: 18790372     Source Type: Journal    
DOI: 10.1016/j.coi.2014.01.004     Document Type: Review

References (65)

1. Grivennikov S.I., Greten F.R., Karin M. Immunity, inflammation, and cancer. Cell 2010, 140:883-899.
2. Shankaran V., Ikeda H., Bruce A.T., White J.M., Swanson P.E., Old L.J., Schreiber R.D. IFNgamma and lymphocytes prevent primary tumor development and shape tumor immunogenicity. Nature 2001, 410:1107-1111.
3. Dunn G.P., Koebel C.M., Schreiber R.D. Interferons, immunity and cancer immunoediting. Nat Rev Immunol 2006, 6:836-848.
4. Burnet M. Cancer; a biological approach. I. The processes of control. Br Med J 1957, 1:779-786.
5. Schreiber R.D., Old L.J., Smyth M.J. Cancer immunoediting: integrating immunity's roles in cancer suppression and promotion. Science 2011, 331:1565-1570.
6. Dunn G.P., Old L.J., Schreiber R.D. The immunobiology of cancer immunosurveillance and immunoediting. Immunity 2004, 21:137-148.
7. Hanahan D., Weinberg R.A. Hallmarks of cancer: the next generation. Cell 2011, 144:646-674.
8. Matsushita H., Vesely M.D., Koboldt D.C., Rickert C.G., Uppaluri R., Magrini V.J., Arthur C.D., White J.M., Chen Y.S., Shea L.K., et al. Cancer exome analysis reveals a T-cell-dependent mechanism of cancer immunoediting. Nature 2012, 482:400-404.
9. DuPage M., Mazumdar C., Schmidt L.M., Cheung A.F., Jacks T. Expression of tumor-specific antigens underlies cancer immunoediting. Nature 2012, 482:405-409.
10. DuPage M., Cheung A.F., Mazumdar C., Winslow M.M., Bronson R., Schmidt L.M., Crowley D., Chen J., Jacks T. Endogenous T cell responses to antigens expressed in lung adenocarcinomas delay malignant tumor progression. Cancer Cell 2011, 19:72-85.
11. Castle J.C., Kreiter S., Diekmann J., Lower M., van de Roemer N., de Graaf J., Selmi A., Diken M., Boegel S., Paret C., et al. Exploiting the mutanome for tumor vaccination. Cancer Res 2012, 72:1081-1091.
12. Robbins P.F., Lu Y.C., El-Gamil M., Li Y.F., Gross C., Gartner J., Lin J.C., Teer J.K., Cliften P., Tycksen E., et al. Mining exomic sequencing data to identify mutated antigens recognized by adoptively transferred tumor-reactive T cells. Nat Med 2013, 19:747-752.
13. van Rooij N., van Buuren M.M., Philips D., Velds A., Toebes M., Heemskerk B., van Dijk L.J., Behjati S., Hilkmann H., El Atmioui D., et al. Tumor exome analysis reveals neoantigen-specific T-cell reactivity in an ipilimumab-responsive melanoma. J Clin Oncol 2013, 10:e439-e442.
14. von Boehmer L., Mattle M., Bode P., Landshammer A., Schafer C., Nuber N., Ritter G., Old L., Moch H., Schafer N., et al. NY-ESO-1-specific immunological pressure and escape in a patient with metastatic melanoma. Cancer Immunol 2013, 13:12.
15. Nicholaou T., Chen W., Davis I.D., Jackson H.M., Dimopoulos N., Barrow C., Browning J., Macgregor D., Williams D., Hopkins W., et al. Immunoediting and persistence of antigen-specific immunity in patients who have previously been vaccinated with NY-ESO-1 protein formulated in ISCOMATRIX. Cancer Immunol Immunotherapy 2011, 60:1625-1637.
16. O'Sullivan T., Saddawi-Konefka R., Vermi W., Koebel C.M., Arthur C., White J.M., Uppaluri R., Andrews D.M., Ngiow S.F., Teng M.W., et al. Cancer immunoediting by the innate immune system in the absence of adaptive immunity. J Exp Med 2012, 209:1869-1882.
17. Vesely M.D., Kershaw M.H., Schreiber R.D., Smyth M.J. Natural innate and adaptive immunity to cancer. Annu Rev Immunol 2011, 29:235-271.
18. Diamond M.S., Kinder M., Matsushita H., Mashayekhi M., Dunn G.P., Archambault J.M., Lee H., Arthur C.D., White J.M., Kalinke U., et al. Type I interferon is selectively required by dendritic cells for immune rejection of tumors. J Exp Med 2011, 208:1989-2003.
19. Fuertes M.B., Kacha A.K., Kline J., Woo S.R., Kranz D.M., Murphy K.M., Gajewski T.F. Host type I IFN signals are required for antitumor CD8+ T cell responses through CD8{alpha}+ dendritic cells. J Exp Med 2011, 208:2005-2016.
20. Senovilla L., Vitale I., Martins I., Tailler M., Pailleret C., Michaud M., Galluzzi L., Adjemian S., Kepp O., Niso-Santano M., et al. An immunosurveillance mechanism controls cancer cell ploidy. Science 2012, 337:1678-1684.
21. Croxford J.L., Tang M.L., Pan M.F., Huang C.W., Kamran N., Phua C.M., Chng W.J., Ng S.B., Raulet D.H., Gasser S. ATM-dependent spontaneous regression of early Emu-myc-induced murine B-cell leukemia depends on natural killer and T cells. Blood 2013, 121:2512-2521.
22. Iannello A., Thompson T.W., Ardolino M., Lowe S.W., Raulet D.H. p53-dependent chemokine production by senescent tumor cells supports NKG2D-dependent tumor elimination by natural killer cells. J Exp Med 2013, 210:2057-2069.
23. Gasser S., Orsulic S., Brown E.J., Raulet D.H. The DNA damage pathway regulates innate immune system ligands of the NKG2D receptor. Nature 2005, 436:1186-1190.
24. Liu X.V., Ho S.S., Tan J.J., Kamran N., Gasser S. Ras activation induces expression of Raet1 family NK receptor ligands. J Immunol 2012, 189:1826-1834.
25. Kang T.W., Yevsa T., Woller N., Hoenicke L., Wuestefeld T., Dauch D., Hohmeyer A., Gereke M., Rudalska R., Potapova A., et al. Senescence surveillance of pre-malignant hepatocytes limits liver cancer development. Nature 2011, 479:547-551.
26. Biroccio A., Cherfils-Vicini J., Augereau A., Pinte S., Bauwens S., Ye J., Simonet T., Horard B., Jamet K., Cervera L., et al. TRF2 inhibits a cell-extrinsic pathway through which natural killer cells eliminate cancer cells. Nat Cell Biol 2013, 15:818-828.
27. Willingham S.B., Volkmer J.P., Gentles A.J., Sahoo D., Dalerba P., Mitra S.S., Wang J., Contreras-Trujillo H., Martin R., Cohen J.D., et al. The CD47-signal regulatory protein alpha (SIRPa) interaction is a therapeutic target for human solid tumors. Proc Natl Acad Sci U S A 2012, 109:6662-6667.
28. Weiskopf K., Ring A.M., Ho C.C., Volkmer J.P., Levin A.M., Volkmer A.K., Ozkan E., Fernhoff N.B., van de Rijn M., Weissman I.L., et al. Engineered SIRPalpha variants as immunotherapeutic adjuvants to anticancer antibodies. Science 2013, 341:88-91.
29. Koebel C.M., Vermi W., Swann J.B., Zerafa N., Rodig S.J., Old L.J., Smyth M.J., Schreiber R.D. Adaptive immunity maintains occult cancer in an equilibrium state. Nature 2007, 450:903-907.
30. Teng M.W., Vesely M.D., Duret H., McLaughlin N., Towne J.E., Schreiber R.D., Smyth M.J. Opposing roles for IL-23 and IL-12 in maintaining occult cancer in an equilibrium state. Cancer Res 2012, 72:3987-3996.
31. Wu X., Peng M., Huang B., Zhang H., Wang H., Xue Z., Zhang L., Da Y., Yang D., Yao Z., et al. Immune microenvironment profiles of tumor immune equilibrium and immune escape states of mouse sarcoma. Cancer Lett 2013, 340:124-133.
32. Muller-Hermelink N., Braumuller H., Pichler B., Wieder T., Mailhammer R., Schaak K., Ghoreschi K., Yazdi A., Haubner R., Sander C.A., et al. TNFR1 signaling and IFN-gamma signaling determine whether T cells induce tumor dormancy or promote multistage carcinogenesis. Cancer Cell 2008, 13:507-518.
33. Braumuller H., Wieder T., Brenner E., Assmann S., Hahn M., Alkhaled M., Schilbach K., Essmann F., Kneilling M., Griessinger C., et al. T-helper-1-cell cytokines drive cancer into senescence. Nature 2013, 494:361-365.
34. Mellman I., Coukos G., Dranoff G. Cancer immunotherapy comes of age. Nature 2011, 480:480-489.
35. Gajewski T.F., Fuertes M., Spaapen R., Zheng Y., Kline J. Molecular profiling to identify relevant immune resistance mechanisms in the tumor microenvironment. Curr Opin Immunol 2011, 23:286-292.
36. Mantovani A., Sica A. Macrophages, innate immunity and cancer: balance, tolerance, and diversity. Curr Opin Immunol 2010, 22:231-237.
37. Beavis P.A., Stagg J., Darcy P.K., Smyth M.J. CD73: a potent suppressor of antitumor immune responses. Trends Immunol 2012, 33:231-237.
38. Beavis P.A., Divisekera U., Paget C., Chow M.T., John L.B., Devaud C., Dwyer K., Stagg J., Smyth M.J., Darcy P.K. Blockade of A2A receptors potently suppresses the metastasis of CD73+ tumors. Proc Natl Acad Sci U S A 2013, 110:14711-14716.
39. Wang L., Rubinstein R., Lines J.L., Wasiuk A., Ahonen C., Guo Y., Lu L.F., Gondek D., Wang Y., Fava R.A., et al. VISTA, a novel mouse Ig superfamily ligand that negatively regulates T cell responses. J Exp Med 2011, 208:577-592.
40. Ceeraz S., Nowak E.C., Noelle R.J. B7 family checkpoint regulators in immune regulation and disease. Trends Immunol 2013, 34:556-563.
41. Hobo W., Norde W.J., Schaap N., Fredrix H., Maas F., Schellens K., Falkenburg J.H., Korman A.J., Olive D., van der Voort R., et al. B and T lymphocyte attenuator mediates inhibition of tumor-reactive CD8+ T cells in patients after allogeneic stem cell transplantation. J Immunol 2012, 189:39-49.
42. Fourcade J., Sun Z., Pagliano O., Guillaume P., Luescher I.F., Sander C., Kirkwood J.M., Olive D., Kuchroo V., Zarour H.M. CD8(+) T cells specific for tumor antigens can be rendered dysfunctional by the tumor microenvironment through upregulation of the inhibitory receptors BTLA and PD-1. Cancer Res 2012, 72:887-896.
43. Marabelle A., Kohrt H., Sagiv-Barfi I., Ajami B., Axtell R.C., Zhou G., Rajapaksa R., Green M.R., Torchia J., Brody J., et al. Depleting tumor-specific Tregs at a single site eradicates disseminated tumors. J Clin Investig 2013, 123:2447-2463.
44. Pardoll D.M. The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer 2012, 12:252-264.
45. Vanneman M., Dranoff G. Combining immunotherapy and targeted therapies in cancer treatment. Nat Rev Cancer 2012, 12:237-251.
46. Hodi F.S., O'Day S.J., McDermott D.F., Weber R.W., Sosman J.A., Haanen J.B., Gonzalez R., Robert C., Schadendorf D., Hassel J.C., et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 2010, 363:711-723.
47. Brahmer J.R., Tykodi S.S., Chow L.Q., Hwu W.J., Topalian S.L., Hwu P., Drake C.G., Camacho L.H., Kauh J., Odunsi K., et al. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med 2012, 366:2455-2465.
48. Topalian S.L., Hodi F.S., Brahmer J.R., Gettinger S.N., Smith D.C., McDermott D.F., Powderly J.D., Carvajal R.D., Sosman J.A., Atkins M.B., et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med 2012, 366:2443-2454.
49. Wolchok J.D., Kluger H., Callahan M.K., Postow M.A., Rizvi N.A., Lesokhin A.M., Segal N.H., Ariyan C.E., Gordon R.A., Reed K., et al. Nivolumab plus ipilimumab in advanced melanoma. N Engl J Med 2013, 369:122-133.
50. Dranoff G. Immunotherapy at large: balancing tumor immunity and inflammatory pathology. Nat Med 2013, 19:1100-1101.
51. Angell H., Galon J. From the immune contexture to the Immunoscore: the role of prognostic and predictive immune markers in cancer. Curr Opin Immunol 2013, 25:261-267.
52. Galon J., Angell H.K., Bedognetti D., Marincola F.M. The continuum of cancer immunosurveillance: prognostic, predictive, and mechanistic signatures. Immunity 2013, 39:11-26.
53. Mlecnik B., Tosolini M., Charoentong P., Kirilovsky A., Bindea G., Berger A., Camus M., Gillard M., Bruneval P., Fridman W.H., et al. Biomolecular network reconstruction identifies T-cell homing factors associated with survival in colorectal cancer. Gastroenterology 2010, 138:1429-1440.
54. Gajewski T.F., Schreiber H., Fu Y.X. Innate and adaptive immune cells in the tumor microenvironment. Nat Immunol 2013, 14:1014-1022.
55. Balachandran V.P., Cavnar M.J., Zeng S., Bamboat Z.M., Ocuin L.M., Obaid H., Sorenson E.C., Popow R., Ariyan C., Rossi F., et al. Imatinib potentiates antitumor T cell responses in gastrointestinal stromal tumor through the inhibition of Ido. Nat Med 2011, 17:1094-1100.
56. Delahaye N.F., Rusakiewicz S., Martins I., Menard C., Roux S., Lyonnet L., Paul P., Sarabi M., Chaput N., Semeraro M., et al. Alternatively spliced NKp30 isoforms affect the prognosis of gastrointestinal stromal tumors. Nat Med 2011, 17:700-707.
57. Weiss G.R., Grosh W.W., Chianese-Bullock K.A., Zhao Y., Liu H., Slingluff C.L., Marincola F.M., Wang E. Molecular insights on the peripheral and intratumoral effects of systemic high-dose rIL-2 (aldesleukin) administration for the treatment of metastatic melanoma. Clin Cancer Res 2011, 17:7440-7450.
58. Ulloa-Montoya F., Louahed J., Dizier B., Gruselle O., Spiessens B., Lehmann F.F., Suciu S., Kruit W.H., Eggermont A.M., Vansteenkiste J., et al. Predictive gene signature in MAGE-A3 antigen-specific cancer immunotherapy. J Clinl Oncol 2013, 31:2388-2395.
59. Ji R.R., Chasalow S.D., Wang L., Hamid O., Schmidt H., Cogswell J., Alaparthy S., Berman D., Jure-Kunkel M., Siemers N.O., et al. An immune-active tumor microenvironment favors clinical response to ipilimumab. Cancer Immunol Immunotherapy 2012, 61:1019-1031.
60. Halama N., Michel S., Kloor M., Zoernig I., Benner A., Spille A., Pommerencke T., von Knebel D.M., Folprecht G., Luber B., et al. Localization and density of immune cells in the invasive margin of human colorectal cancer liver metastases are prognostic for response to chemotherapy. Cancer Res 2011, 71:5670-5677.
61. Ignatiadis M., Singhal S.K., Desmedt C., Haibe-Kains B., Criscitiello C., Andre F., Loi S., Piccart M., Michiels S., Sotiriou C. Gene modules and response to neoadjuvant chemotherapy in breast cancer subtypes: a pooled analysis. J Clin Oncol 2012, 30:1996-2004.
62. Denkert C., Loibl S., Noske A., Roller M., Muller B.M., Komor M., Budczies J., Darb-Esfahani S., Kronenwett R., Hanusch C., et al. Tumor-associated lymphocytes as an independent predictor of response to neoadjuvant chemotherapy in breast cancer. J Clin Oncol 2010, 28:105-113.
63. Tosolini M., Kirilovsky A., Mlecnik B., Fredriksen T., Mauger S., Bindea G., Berger A., Bruneval P., Fridman W.H., Pages F., et al. Clinical impact of different classes of infiltrating T cytotoxic and helper cells (Th1, th2, treg, th17) in patients with colorectal cancer. Cancer Res 2011, 71:1263-1271.
64. Grivennikov S.I., Wang K., Mucida D., Stewart C.A., Schnabl B., Jauch D., Taniguchi K., Yu G.Y., Osterreicher C.H., Hung K.E., et al. Adenoma-linked barrier defects and microbial products drive IL-23/IL-17-mediated tumor growth. Nature 2012, 491:254-258.
65. Schwabe R.F., Jobin C. The microbiome and cancer. Nat Rev Cancer 2013, 13:800-812.